Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Human Genome Sciences has reacquired rights to the Trail receptor antibodies HGS-ETR1 and HGS-ETR2 from GlaxoSmithKline, in return for a reduction in royalties due to Human Genome if Syncria is commercialized.
Subscribe to our email newsletter
The fees and milestone payments due to HGS under the original Syncria agreement, some of which have already been received, could amount to as much as $183 million and remain unchanged in the amended agreement.
Human Genome Sciences (HGS) is developing its Trail receptor antibodies for the treatment of a broad range of cancers, and the company also announced plans to initiate its third randomized Phase II chemotherapy combination trial of HGS-ETR1 (mapatumumab) by mid-2008 in patients with hepatocellular cancer.
HGS has also reported that a 2002 agreement with the Pharmaceutical Division of Kirin Brewery Company, for joint development of antibodies to Trail receptor 2 has been terminated.
Barry Labinger, executive vice president and chief commercial officer, HGS, said: “We will continue to explore the possibility of bringing in additional new products, as well as forming new partnerships to add expertise and near-term financial resources in support of our pipeline.”